Catheter Ablation for Atrial Fibrillation in Adult Congenital Heart Disease: An International Multi-Center Registry Study

- Jack R. Griffiths MBBS BSc¹, Udi Nussinovitch MD PhD², Jackson J. Liang DO³, Richard Sims MD⁴, Zachary T. Yoneda MD MSCI⁴, Hannah M. Bernstein MD MPH⁵, Mohan N. Viswanathan MD², Paul Khairy MDCM PhD⁶, Uma N. Srivatsa MBBS MAS⁵, David S. Frankel MD⁷, Francis E. Marchlinski MD⁷, Amneet Sandhu MD⁸, M. Benjamin Shoemaker MD MSCI⁴, Sanghamitra Mohanty MD⁹, John D. Burkhardt MD⁹, Andrea Natale MD⁹, Dhanujaya Lakkireddy MD¹⁰, Natasja M. S. De Groot MD PhD¹¹, Edward P. Gerstenfeld MD¹², Jeremy P. Moore MD¹³, Pablo Avila MD¹⁴, Sabine Ernst MD PhD¹, Duy Thai Nguyen MD¹⁵
- ¹ Royal Brompton Hospital (Guy's and St Thomas' NHS Foundation Trust), London, United Kingdom; National Heart Lung Institute, Imperial College London, United Kingdom.
- ² Section of Electrophysiology, Cardiology Division, Stanford University, 870 Quarry Road, Stanford, CA, 94305, United States.
- ³ Electrophysiology, Division of Cardiology, Internal Medicine, University of Michigan, Ann Arbor, Michigan, United States.
- ⁴ Department of Medicine, Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN, United States.
- ⁵ Division of Cardiovascular Medicine, University of California Davis, Sacramento, California, United States.
- ⁶ Montreal Heart Institute, Université de Montréal, Montreal, Canada.
- ⁷ Division of Cardiovascular Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.

- 8 Clinical Cardiac Electrophysiology Section, Division of Cardiology, University of Colorado School of Medicine, Aurora, Colorado, United States.
- ⁹ Texas Cardiac Arrhythmia Institute, Austin, Texas, United States.
- ¹⁰ Kansas City Heart Rhythm Institute, Kansas City, Kansas, United States.
- ¹¹ Department of Cardiology, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands.
- ¹² Section of Cardiac Electrophysiology, Division of Cardiology, University of California San Francisco, California, United States.
- ¹³ Division of Cardiology, Department of Medicine, UCLA Medical Center, Ahmanson/UCLA Adult Congenital Heart Disease Center, Los Angeles, California, USA; UCLA Cardiac Arrhythmia Center, UCLA Health System, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
- ¹⁴ Cardiology Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain.
- Section of Electrophysiology, Cardiology Division, Stanford University, 300 Pasteur Ave, Stanford, California, USA.

ABSTRACT

Background: Life expectancies for patients with congenital heart disease (CHD) have dramatically increased in recent years, accompanied by a rise in atrial fibrillation (AF) prevalence. Data on AF ablation strategy and outcomes are limited in CHD.

Objective: We aimed to investigate the characteristics of CHD patients presenting for AF ablation and their outcomes.

Methods: A multicenter, retrospective analysis was performed of CHD patients undergoing AF ablation between 2004 and 2020 at 13 participating centers. The severity of CHD was classified using the 2014 PACES/HRS guidelines. Clinical data were collected including ablation strategy and follow-up. One-year complete procedural success was defined as freedom from atrial tachycardia or AF in the absence of antiarrhythmic drugs (AADs) or including previously failed AADs (partial success).

Results Of 240 patients, 127 (53.4%) had persistent AF, 62.5% were male, and mean age was 55.2 ± 0.9 years. CHD complexity categories included 147 (61.3%) simple, 69 (28.8%) intermediate and 25 (10.4%) severe. The most common CHD type was atrial septal defect (n=78). More complex CHD conditions included transposition of the great arteries (n=14), anomalous pulmonary veins (n=13), tetralogy of Fallot (n=8), cor triatriatum (n=7), single ventricle physiology (n=2), among others. The majority (71.3%) of patients had trialled at least one AAD. Forty-six patients (22.1%) had a reduced systemic ventricular ejection fraction < 50%, and the mean left atrial diameter was 44.1 ± 0.7 mm. Pulmonary vein isolation (PVI) was performed in 227 patients (94.6%); additional ablation strategies included left atrial linear ablations (25.4%), CFAE (19.2%), and cavotricuspid isthmus ablation (40.8%). One-year complete and partial success rates were 45.0% and 20.5%, respectively, with no significant difference in the rate of complete success between complexity groups. Overall, 38 patients (15.8%) required more than one ablation procedure. There were 3 (1.3%) major and 13 (5.4%) minor procedural complications.


- Conclusions: AF ablation in CHD was safe and resulted in AF control in the majority of patients, regardless of complexity. Future work should address the most appropriate ablation
- targets in this challenging population.

FIGURE LEGEND

- Figure 1. Classification of CHD complexity in patients who had undergone AF ablation.
- Figure 2. Complete and partial success rates of AF ablation in congenital heart disease (CHD).

Figure 1

Petrone



Patients with multiple CHD were classified based on the most complex abnormality. 6 patients had more than one severe lesion, 4 patients had more than one moderate lesion, and 10 patients had more than one simple lesion; ASD, atrial septal defect; AV, = aortic valve; AVSD = atrioventricular septal defect; ccTGA = congenitally corrected transposition of the great arteries; IVC = inferior vena cava; MV = mitral valve; PV = pulmonary veins; PVOD = pulmonary vascular obstructive disease; SVC = superior vena cava; VSD = ventricular septal defect.

